Gm1 Gangliosidosis Epidemiology Forecast

DelveInsight's ' GM1 Gangliosidosis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted GM1 Gangliosidosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


GM1 Gangliosidosis Understanding

The DelveInsight GM1 Gangliosidosis epidemiology report gives a thorough understanding of the GM1 Gangliosidosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for GM1 Gangliosidosis in the US, Europe, and Japan. The report covers the detailed information of the GM1 Gangliosidosis epidemiology scenario in seven major countries (US, EU5, and Japan).


GM1 Gangliosidosis Epidemiology Perspective by DelveInsight

The GM1 Gangliosidosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The GM1 Gangliosidosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The GM1 Gangliosidosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


GM1 Gangliosidosis Detailed Epidemiology Segmentation

The GM1 Gangliosidosis epidemiology covered in the report provides historical as well as forecasted GM1 Gangliosidosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight GM1 Gangliosidosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The GM1 Gangliosidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The GM1 Gangliosidosis Epidemiology Report and Model provide an overview of the risk factors and global trends of GM1 Gangliosidosis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of GM1 Gangliosidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of GM1 Gangliosidosis
  • The report provides the segmentation of the GM1 Gangliosidosis epidemiology


Report Highlights

  • 11-Year Forecast of GM1 Gangliosidosis epidemiology
  • 7MM Coverage
  • Total Cases of GM1 Gangliosidosis
  • Total Cases of GM1 Gangliosidosis according to segmentation
  • Diagnosed cases of GM1 Gangliosidosis


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GM1 Gangliosidosis?
  • What are the key findings pertaining to the GM1 Gangliosidosis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of GM1 Gangliosidosis across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the GM1 Gangliosidosis?
  • What are the currently available treatments of GM1 Gangliosidosis?


Reasons to buy

  • The GM1 Gangliosidosis Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global GM1 Gangliosidosis market
  • Quantify patient populations in the global GM1 Gangliosidosis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GM1 Gangliosidosis therapeutics in each of the markets covered
  • Understand the magnitude of GM1 Gangliosidosis population by its epidemiology
  • The GM1 Gangliosidosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of GM1 Gangliosidosis

3.  GM1 Gangliosidosis: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1.  GM1 Gangliosidosis Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1.  GM1 Gangliosidosis Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1.  GM1 Gangliosidosis Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1.  GM1 Gangliosidosis Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1.  GM1 Gangliosidosis Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1.  GM1 Gangliosidosis Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1.  GM1 Gangliosidosis Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1.  GM1 Gangliosidosis Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1.  GM1 Gangliosidosis Treatment and Management

6.2.  GM1 Gangliosidosis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1   GM1 Gangliosidosis Epidemiology in 7MM (2017-2030)

Table 2  GM1 Gangliosidosis Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3  GM1 Gangliosidosis Epidemiology in the United States (2017-2030)

Table 4  GM1 Gangliosidosis Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5  GM1 Gangliosidosis Epidemiology in Germany (2017-2030)

Table 6  GM1 Gangliosidosis Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7  GM1 Gangliosidosis Epidemiology in France (2017-2030)

Table 8  GM1 Gangliosidosis Diagnosed and Treatable Cases in France (2017-2030)

Table 9  GM1 Gangliosidosis Epidemiology in Italy (2017-2030)

Table 10 GM1 Gangliosidosis Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 GM1 Gangliosidosis Epidemiology in Spain (2017-2030)

Table 12 GM1 Gangliosidosis Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 GM1 Gangliosidosis Epidemiology in the United Kingdom (2017-2030)

Table 14 GM1 Gangliosidosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 GM1 Gangliosidosis Epidemiology in Japan (2017-2030)

Table 16 GM1 Gangliosidosis Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1  GM1 Gangliosidosis Epidemiology in 7MM (2017-2030)

Figure 2  GM1 Gangliosidosis Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3  GM1 Gangliosidosis Epidemiology in the United States (2017-2030)

Figure 4  GM1 Gangliosidosis Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5  GM1 Gangliosidosis Epidemiology in Germany (2017-2030)

Figure 6  GM1 Gangliosidosis Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7  GM1 Gangliosidosis Epidemiology in France (2017-2030)

Figure 8  GM1 Gangliosidosis Diagnosed and Treatable Cases in France (2017-2030)

Figure 9  GM1 Gangliosidosis Epidemiology in Italy (2017-2030)

Figure 10 GM1 Gangliosidosis Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 GM1 Gangliosidosis Epidemiology in Spain (2017-2030)

Figure 12 GM1 Gangliosidosis Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 GM1 Gangliosidosis Epidemiology in the United Kingdom (2017-2030)

Figure 14 GM1 Gangliosidosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 GM1 Gangliosidosis Epidemiology in Japan (2017-2030)

Figure 16 GM1 Gangliosidosis Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • GM1 Gangliosidosis Epidemiology
  • GM1 Gangliosidosis
  • GM1 Gangliosidosis Pipeline
  • GM1 Gangliosidosis Companies
  • GM1 Gangliosidosis prevalent popu...
  • GM1 Gangliosidosis incident popul...
  • GM1 Gangliosidosis patients diagn...
  • GM1 Gangliosidosis treatment algo...

Forward to Friend

Need A Quote